Mouse methylome studies SRP340739 Track Settings
 
Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development [Lung]

Track collection: Mouse methylome studies

+  All tracks in this collection (596)

Maximum display mode:       Reset to defaults   
Select views (Help):
CpG reads ▾       AMR       CpG methylation ▾       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  AMR  CpG methylation  PMD  HMR 
experiment
SRX12566134 
SRX12566135 
SRX12566136 
SRX12566137 
SRX12566138 
SRX12566139 
SRX12566140 
SRX12566141 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 Configure
 SRX12566134  CpG methylation  Lung / SRX12566134 (CpG methylation)   Schema 
hide
 SRX12566134  HMR  Lung / SRX12566134 (HMR)   Schema 
hide
 SRX12566135  HMR  Lung / SRX12566135 (HMR)   Schema 
hide
 Configure
 SRX12566135  CpG methylation  Lung / SRX12566135 (CpG methylation)   Schema 
hide
 Configure
 SRX12566136  CpG methylation  Lung / SRX12566136 (CpG methylation)   Schema 
hide
 SRX12566136  HMR  Lung / SRX12566136 (HMR)   Schema 
hide
 Configure
 SRX12566137  CpG methylation  Lung / SRX12566137 (CpG methylation)   Schema 
hide
 SRX12566137  HMR  Lung / SRX12566137 (HMR)   Schema 
hide
 SRX12566138  HMR  Lung / SRX12566138 (HMR)   Schema 
hide
 Configure
 SRX12566138  CpG methylation  Lung / SRX12566138 (CpG methylation)   Schema 
hide
 SRX12566139  HMR  Lung / SRX12566139 (HMR)   Schema 
hide
 Configure
 SRX12566139  CpG methylation  Lung / SRX12566139 (CpG methylation)   Schema 
hide
 Configure
 SRX12566140  CpG methylation  Lung / SRX12566140 (CpG methylation)   Schema 
hide
 SRX12566140  HMR  Lung / SRX12566140 (HMR)   Schema 
hide
 Configure
 SRX12566141  CpG methylation  Lung / SRX12566141 (CpG methylation)   Schema 
hide
 SRX12566141  HMR  Lung / SRX12566141 (HMR)   Schema 
    

Study title: Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development
SRA: SRP340739
GEO: GSE185615
Pubmed: 35110400

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX12566134 Lung 0.525 2.8 26906 2258.9 76 1045.3 147 68891.7 0.985 title: GSM5620634 Pre-malignant_K_PBAT_1, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566135 Lung 0.522 2.5 24833 2405.3 48 1047.8 131 82829.6 0.985 title: GSM5620635 Pre-malignant_K_PBAT_2, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566136 Lung 0.549 2.3 26188 2275.0 42 1592.7 69 124416.1 0.985 title: GSM5620636 Pre-malignant_K_PBAT_3, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566137 Lung 0.531 2.6 25604 2299.7 90 988.4 154 72382.8 0.985 title: GSM5620637 Pre-malignant_K_PBAT_4, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566138 Lung 0.574 3.2 31265 1957.1 59 1042.5 194 62496.6 0.985 title: GSM5620638 Pre-malignant_KT_PBAT_1, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566139 Lung 0.544 2.3 26711 2211.0 50 860.3 98 120429.3 0.985 title: GSM5620639 Pre-malignant_KT_PBAT_2, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566140 Lung 0.537 2.6 25997 2234.0 64 1228.6 145 76398.4 0.984 title: GSM5620640 Pre-malignant_KT_PBAT_3, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung
SRX12566141 Lung 0.557 3.0 29478 1993.0 54 1032.5 109 69688.4 0.985 title: GSM5620641 Pre-malignant_KT_PBAT_4, Mus musculus, Bisulfite-Seq; source_name: Pre-malignant lung epithelial cells; strain: C57BL/6J-129Sv; tissue: lung

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.